Highest-materiality recent filing
QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance
GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds
Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.
CFO Joseph M. Busky to retire effective June 30, 2026
Joseph M. Busky notified QuidelOrtho of his retirement on February 9, 2026.
QuidelOrtho reports FY25 revenue $2.73B, adjusted EBITDA $597M; guides FY26 revenue $2.7-2.9B
FY25 total revenue $2.73B in line with guidance; Labs revenue +6% as reported, non-respiratory +5% ex Donor Screening.
QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY
Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.
QuidelOrtho Q3 revenue $700M (-4% YoY); GAAP loss $10.78/sh on $701M impairment; Adj EPS $0.80
Total revenue $700M, down 4% YoY; non-respiratory revenue up 5% as reported, 6% constant currency ex-Donor Screening.
QuidelOrtho refinances with $1.15B Term Loan A, $1.45B Term Loan B, $700M revolver
New credit facility includes $1.15B 5-yr Term Loan A, $1.45B 7-yr Term Loan B, $700M revolver, and $100M delayed draw Term Loan A (undrawn).
QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance
Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
QuidelOrtho Q1 revenue $693M, +5% ex-COVID/Donor; adjusted EPS $0.74 vs $0.44 YoY
Total revenue $693M, -3% reported due to lower COVID/Donor; ex-COVID/Donor +5% as reported and +6% constant currency.
QuidelOrtho appoints KPMG as auditor, dismisses EY; material weaknesses disclosed
Audit Committee selected KPMG as independent auditor for FY 2025, dismissing EY effective Feb 28, 2025, after competitive process.
Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.
Carlyle sells 8.26M QuidelOrtho shares at $35.31; two Carlyle directors resign
Carlyle Partners VI sells 8,260,183 QDEL shares at $35.31/share; company receives no proceeds.
QuidelOrtho Q3 GAAP net loss $20M ($0.30 EPS); revenue $727M; reinstates 2024 guidance
Revenue $727M vs $744M YoY; Labs revenue grew 4% as reported (5% constant currency).
QuidelOrtho Q2 2024: revenue $637M, GAAP diluted loss ($2.20)/share
Total revenue $637M, down 4% YoY; lower COVID-19 revenue was primary driver.
QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO
Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).
QuidelOrtho appoints Brian J. Blaser as CEO effective May 6, 2024
Blaser, ex-Abbott EVP Diagnostic Products, replaces interim CEO Michael Iskra and interim President Robert Bujarski.
the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer (“COO”), effective November 15, 2024.
Joseph M. Busky, the Company’s Chief Financial Officer, assuming additional responsibilities, including oversight of the Company’s Information Technology function, on November 18, 2024
In addition, the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer, effective as of the Effective Date.
The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).
The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).
The Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) has appointed Brian J. Blaser to serve as the Company’s President and Chief Executive Officer, effective as of May 6, 2024 (the “Effective Date”).
each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.
In addition, effective as of May 15, 2024, the Board expanded its size from ten to eleven directors and appointed Mr. Blaser to serve as a director until the Company’s 2025 Annual Meeting of Stockholders.
each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.
Max materiality 0.85 · Median 0.65 · Most common event earnings